Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03523858 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple Sclerosis

Study acronym: CONSONANCE
StatusActive, Not Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

The 50 most recent of 67 record versions are accounted for below. See every version on ClinicalTrials.gov ↗

  1. Trial sites reduced: 124 → 120 locationsv67
  2. Primary and study completion dates: Nov 12, 2026 to Oct 22, 2026v66
  3. Primary completion date: Jan 15, 2026 to Nov 12, 2026 Completion date: Dec 4, 2026 to Nov 12, 2026v65 Show 1 more changeShow less
    • Completion date: Dec 4, 2026 to Nov 12, 2026
  4. Study sites: 125 to 124v64
  5. Study sites revised (125)v63 See this version in full on ClinicalTrials.gov ↗
Show 45 earlier versionsHide 45 earlier versions
  1. Study sites: 126 to 125v62
  2. 3 versions Re-verified since Aug 9, 2024, no change to tracked fieldsv59-v61
  3. Study sites revised (126)v58 See this version in full on ClinicalTrials.gov ↗
  4. 2 versions Re-verified since Mar 12, 2024, no change to tracked fieldsv56-v57
  5. Site details revised at 1 of 126 sitesv55
  6. 3 versions Re-verified since Aug 4, 2023, no change to tracked fieldsv52-v54
  7. Study sites: 122 to 126v51
  8. Study sites: 126 to 122v50
  9. Study sites revised (126)v49 See this version in full on ClinicalTrials.gov ↗
  10. Study sites revised (126)v48 See this version in full on ClinicalTrials.gov ↗
  11. Study sites revised (126)v47 See this version in full on ClinicalTrials.gov ↗
  12. Site details revised at 2 of 126 sitesv46
  13. Enrollment target: estimated 900 to confirmed 927 Study sites revised (126)v45 Show 1 more changeShow less
    • Study sites revised (126)

    See this version in full on ClinicalTrials.gov ↗

  14. Trial status: Recruiting to Active, Not Recruiting Study sites: 135 to 126v44 Show 1 more changeShow less
    • Study sites: 135 to 126
  15. Trial status: Active, Not Recruiting to Recruiting Study sites: 126 to 135v43 Show 1 more changeShow less
    • Study sites: 126 to 135
  16. Trial status: Recruiting to Active, Not Recruiting Study sites: 135 to 126v42 Show 1 more changeShow less
    • Study sites: 135 to 126
  17. Site details revised at 1 of 135 sitesv41
  18. Site details revised at 7 of 135 sitesv40
  19. Re-verified, no change to tracked fieldsv39
  20. Site details revised at 24 of 135 sitesv38
  21. Site details revised at 19 of 135 sitesv37
  22. Primary completion date: Dec 5, 2025 to Jan 15, 2026 Site details revised at 11 of 135 sitesv36 Show 1 more changeShow less
    • Site details revised at 11 of 135 sites
  23. Primary completion date: Sep 30, 2023 to Dec 5, 2025 Completion date: Jun 26, 2025 to Dec 4, 2026 · Study sites revised (135)v35 Show 2 more changesShow less
    • Completion date: Jun 26, 2025 to Dec 4, 2026
    • Study sites revised (135)

    See this version in full on ClinicalTrials.gov ↗

  24. Site details revised at 18 of 135 sitesv34
  25. Site details revised at 12 of 135 sitesv33
  26. Study sites revised (135)v32 See this version in full on ClinicalTrials.gov ↗
  27. Site details revised at 6 of 135 sitesv31
  28. Site details revised at 8 of 135 sitesv30
  29. Eligibility criteria expanded, about 95 words Secondary endpoints: 27 to 26 · Site details revised at 4 of 135 sitesv29 Show 2 more changesShow less
    • Secondary endpoints: 27 to 26
    • Site details revised at 4 of 135 sites

    See this version in full on ClinicalTrials.gov ↗

  30. Site details revised at 3 of 135 sitesv28
  31. Study sites: 134 to 135 Primary completion date: Mar 27, 2024 to Sep 30, 2023v27 Show 1 more changeShow less
    • Primary completion date: Mar 27, 2024 to Sep 30, 2023
  32. Site details revised at 3 of 134 sitesv26
  33. Site details revised at 7 of 134 sitesv25
  34. Completion date: Sep 25, 2025 to Jun 26, 2025v24
  35. Trial status: Active, Not Recruiting to Recruiting Enrollment target: 633 to 900 · Study sites: 126 to 134v23 Show 2 more changesShow less
    • Enrollment target: 633 to 900
    • Study sites: 126 to 134
  36. Study sites: 127 to 126v22
  37. Study sites: 120 to 127v21
  38. Study sites revised (120)v20 See this version in full on ClinicalTrials.gov ↗
  39. Study sites: 122 to 120v19
  40. Primary completion date: Sep 29, 2023 to Mar 27, 2024 Primary endpoints revised (2) · Enrollment target: 628 to 633 · Completion date: Sep 28, 2024 to Sep 25, 2025 · 3 morev18 Show 6 more changesShow less
    • Primary endpoints revised (2)
    • Enrollment target: 628 to 633
    • Completion date: Sep 28, 2024 to Sep 25, 2025
    • Eligibility criteria expanded, about 207 words
    • Secondary endpoints: 21 to 27
    • Study sites revised (122)

    See this version in full on ClinicalTrials.gov ↗

  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study is a prospective, multicenter, open-label, single-arm effectiveness and safety study in participants with progressive multiple sclerosis (PMS).
Trial Details
NCT Number NCT03523858
Lead Sponsor Hoffmann-La Roche
Conditions Progressive Multiple Sclerosis (PMS)
Enrollment 927 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov